-
Mashup Score: 0
The effects of the COVID-19 pandemic continue to constrain health-care staff and resources worldwide, despite the availability of effective vaccines. Aerosol-generating procedures such as endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cause of SARS-CoV-2 spread in hospitals. Plasma Epstein-Barr virus (EBV) DNA is considered the most accurate…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The Lancet Oncology - 1 year(s) ago
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our last issue of the year is now live! Read the December 2022 issue here: https://t.co/tyRoZxwb4X With papers on #childhoodcancer, #sarcoma, #imaging for #metastases, #breastcancer, #kidneycancer, #nasopharyngealcarcinoma, #prostatecancer #radiotherapy and much more https://t.co/7pzCXfnzSd
-
-
Mashup Score: 0
Patients with higher intratumoral bacterial loads had significantly worse disease-free survival, distant metastasis-free survival, and overall survival.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Intratumoral bacterial load is associated with survival outcomes in patients with #nasopharyngealCarcinoma, according to research published in @JAMAOnc. https://t.co/MsboxQ07UK
-
-
Mashup Score: 1Nimotuzumab May Improve Survival in Nasopharyngeal Carcinoma - 2 year(s) ago
Adding nimotuzumab to concomitant chemoradiotherapy may improve 5-year survival in locally advanced nasopharyngeal carcinoma.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding nimotuzumab to concomitant chemoradiotherapy may improve long-term survival in patients with locally advanced #nasopharyngealCarcinoma, according to research presented at the @ASCO conference #ASCO22. https://t.co/sEOesa5mRk #CCRT
-
-
Mashup Score: 2
Background Radiotherapy is the first-line treatment for patients nasopharyngeal carcinoma (NPC), but its therapeutic efficacy is poor in some patients due to radioresistance. Adoptive T cell-based immunotherapy has also shown promise to control NPC; however, its antitumor efficacy may be attenuated by an immunosuppressive tumor microenvironment. Exosomes derived from γδ-T cells (γδ-T-Exos) have…
Categories: General Medicine News, Latest HeadlinesTweet-
#Nasopharyngealcarcinoma treatment using exosomes derived from γδ-T #cells synergized with radiotherapy @hkuniversity https://t.co/et20kZ8geR https://t.co/ZsUv8WibDc
-
-
Mashup Score: 0
The risk score can improve upon EBV-based screening, according to researchers.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A #PolygenicRiskScore can identify patients at high risk of developing #NasopharyngealCarcinoma with relatively good performance, according to researchers. Study with @Nature. https://t.co/xVTrW6s3Cw
-
-
Mashup Score: 0
The risk score can improve upon EBV-based screening, according to researchers.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A polygenic risk score can identify patients at high risk of developing nasopharyngeal carcinoma with relatively good performance, according to researchers. Study with @NaturePortfolio. https://t.co/otSsJWP7OG #NasopharyngealCarcinoma
-
-
Mashup Score: 2
Findings from the randomized phase 3 RATIONALE-309 trial presented during the April ASCO Plenary Series by Li Zhang, MD, of the Sun Yat-sen University Cancer Center in Guangzhou, China, substantiate the benefit of adding an immune checkpoint inhibitor to chemotherapy in the first-line setting for advanced nasopharyngeal carcinoma (NPC).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Proud to bring the @OncoAlert 🚨Wrap Up for the April #ASCOPlenarySeries 🌐 RATIONALE3⃣0⃣9⃣by Dr.Zhang🇨🇳 tislelizumab🧪+chemo strengthens upfront ICI🏁in #nasopharyngealcarcinoma 👃 Kudos to our collaborators at @ASCO ‼️ @DrHaddadRobert ASCO Daily News https://t.co/omwLAebQHu https://t.co/tdNj0e0Y5R
-
-
Mashup Score: 3
Findings from the randomized phase 3 RATIONALE-309 trial presented during the April ASCO Plenary Series by Li Zhang, MD, of the Sun Yat-sen University Cancer Center in Guangzhou, China, substantiate the benefit of adding an immune checkpoint inhibitor to chemotherapy in the first-line setting for advanced nasopharyngeal carcinoma (NPC).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
News from #ASCOPlenarySeries: RATIONALE-309 findings for tislelizumab + chemo bolster upfront use of ICI in advanced #nasopharyngealcarcinoma. https://t.co/3dxixaGRM9 #ASCODailyNews #hncsm
-
-
Mashup Score: 0
Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Now in the April issue: Elective upper-neck vs whole-neck #irradiation of the uninvolved #neck in patients with #nasopharyngealcarcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial https://t.co/ujbIkGFtbe #hncsm
-
New Policy Review: International recommendations for plasma #EpsteinBarrVirus DNA measurement in #nasopharyngealcarcinoma in resource-constrained settings: lessons from the #COVID19 pandemic https://t.co/GHKiuW3sMh